Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q2)Dec 31, 2024 | (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 397.27%2.83M | 130.52%944K | -34.25%-4.8M | -132.29%-524K | 93.07%-229K | 27.49%-952K | -434.20%-3.09M | 85.04%-3.57M | 135.63%1.62M | 16.03%-3.31M |
Net income from continuing operations | -110.60%-1.89M | 23.72%-1.67M | -7.62%-8.33M | -11.66%-2.77M | -71.76%-2.48M | 46.70%-896K | -2.29%-2.19M | 53.00%-7.74M | 29.54%-2.48M | 61.46%-1.45M |
Depreciation and amortization | -4.58%250K | -3.45%252K | 16.24%1.05M | 2.38%258K | -4.35%264K | 31.66%262K | 51.74%261K | 56.35%899K | 54.60%252K | 80.39%276K |
Other non cash items | 1.97%207K | -11.45%201K | -15.90%836K | 26.82%227K | -15.17%179K | -21.32%203K | -34.39%227K | 126.94%994K | 57.02%179K | 93.58%211K |
Change In working capital | 458.45%3.71M | 194.22%1.68M | -151.65%-407K | -64.74%1.04M | 151.67%1.38M | -153.68%-1.04M | -293.28%-1.78M | 108.03%788K | 248.16%2.94M | -390.96%-2.66M |
-Change in receivables | 178.79%1.49M | 85.44%-297K | -409.42%-973K | -25.74%782K | 253.58%2.17M | -267.05%-1.89M | 31.70%-2.04M | 92.40%-191K | 17.13%1.05M | 114.20%614K |
-Change in inventory | -127.59%-253K | 374.91%1.5M | 45.64%-1.31M | -104.71%-118K | -2.02%-1.56M | 224.09%917K | 79.33%-546K | 56.61%-2.41M | -49.74%2.5M | -18.59%-1.53M |
-Change in payables and accrued expense | 569.14%1.9M | -19.45%708K | -58.06%1.75M | 1,071.88%311K | 153.59%963K | 46.92%-405K | -87.00%879K | 644.13%4.17M | 99.48%-32K | -145.85%-1.8M |
-Change in other current assets | -19.33%121K | 54.88%-97K | 4.12%-163K | 54.70%-82K | -157.14%-16K | -29.25%150K | 6.11%-215K | 69.03%-170K | 58.00%-181K | -90.38%28K |
-Change in other working capital | 141.27%456K | -197.14%-136K | 147.46%290K | 134.80%142K | -824.00%-181K | 176.52%189K | 636.84%140K | -41.44%-611K | 67.10%-408K | -97.10%25K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 397.27%2.83M | 130.52%944K | -34.25%-4.8M | -132.29%-524K | 93.07%-229K | 27.49%-952K | -434.20%-3.09M | 85.04%-3.57M | 135.63%1.62M | 16.05%-3.31M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 24.20%-119K | -9.39%-198K | 16.70%-853K | 5.02%-265K | 38.88%-250K | -1,081.25%-157K | 48.58%-181K | -28.48%-1.02M | -82.35%-279K | -258.77%-409K |
Net PPE purchase and sale | 24.20%-119K | -9.39%-198K | 16.70%-853K | 5.02%-265K | 38.88%-250K | -1,081.25%-157K | 48.58%-181K | -28.48%-1.02M | -82.35%-279K | -258.77%-409K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 24.20%-119K | -9.39%-198K | 16.70%-853K | 5.02%-265K | 38.88%-250K | -1,081.25%-157K | 48.58%-181K | -28.48%-1.02M | -82.35%-279K | -258.77%-409K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -253.60%-2.39M | -140.81%-830K | -39.70%3.92M | -25.71%182K | -96.66%145K | 35.37%1.55M | 170.48%2.03M | -68.27%6.49M | -82.36%245K | 4.35M |
Net issuance payments of debt | -253.60%-2.39M | -140.81%-830K | -23.54%3.77M | 124.59%151K | -99.04%35K | 35.37%1.55M | 170.48%2.03M | 0.96%4.94M | -144.20%-614K | --3.65M |
Net common stock issuance | ---- | ---- | --0 | --0 | ---- | ---- | ---- | -90.01%1.56M | --859K | ---- |
Proceeds from stock option exercised by employees | ---- | ---- | --141K | --31K | ---- | ---- | ---- | --0 | --0 | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -253.60%-2.39M | -140.81%-830K | -39.70%3.92M | -25.71%182K | -96.66%145K | 35.37%1.55M | 170.48%2.03M | -68.27%6.49M | -82.36%245K | --4.35M |
Net cash flow | ||||||||||
Beginning cash position | -50.92%559K | -72.97%643K | 390.52%2.38M | 58.23%1.25M | 908.92%1.58M | 272.22%1.14M | 390.52%2.38M | -89.71%485K | -79.23%790K | -98.00%157K |
Current changes in cash | -27.19%324K | 93.23%-84K | -191.66%-1.74M | -138.20%-607K | -152.76%-334K | 398.66%445K | -592.74%-1.24M | 144.80%1.89M | 147.88%1.59M | 115.63%633K |
End cash Position | -44.26%883K | -50.92%559K | -72.97%643K | -72.97%643K | 58.23%1.25M | 908.92%1.58M | 272.22%1.14M | 390.52%2.38M | 390.52%2.38M | -79.23%790K |
Free cash flow | 344.45%2.71M | 122.79%746K | -22.69%-5.65M | -158.71%-789K | 87.10%-479K | 15.02%-1.11M | -251.66%-3.27M | 81.34%-4.61M | 128.55%1.34M | 8.32%-3.71M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |